Key Points
- Tcg Crossover Gp II, LLC bought a total of 9,357 Surrozen shares across Jan 30–Feb 3 for roughly $202,534, raising its direct holdings to 639,141 shares valued at about $13.67 million (a 0.67% increase from the Jan 30 trade).
- Shares were up ~4.4% intraday, but Surrozen recently reported a steep quarterly EPS miss (‑$3.61 vs. est. ‑$1.17) and very negative margins; analysts are mixed overall with a "Moderate Buy" consensus and an average price target of $32.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock in a transaction dated Monday, February 2nd. The shares were bought at an average cost of $21.38 per share, with a total value of $15,628.78. Following the completion of the acquisition, the insider owned 639,507 shares of the company's stock, valued at $13,672,659.66. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Tcg Crossover Gp Ii, Llc also recently made the following trade(s):
- On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The stock was bought at an average cost of $21.94 per share, for a total transaction of $95,548.70.
- On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The shares were bought at an average price of $21.39 per share, for a total transaction of $91,356.69.
Surrozen Price Performance
Shares of SRZN opened at $23.08 on Wednesday. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94. The company has a 50-day moving average of $20.57 and a two-hundred day moving average of $15.04. The stock has a market cap of $197.80 million, a price-to-earnings ratio of -1.03 and a beta of 0.58.
Surrozen (NASDAQ:SRZN - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. Analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.
Analyst Upgrades and Downgrades
SRZN has been the subject of several recent analyst reports. Lifesci Capital raised Surrozen to a "strong-buy" rating in a research report on Thursday, November 13th. Wall Street Zen raised Surrozen to a "sell" rating in a research note on Friday, November 28th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $32.00.
View Our Latest Research Report on SRZN
Institutional Investors Weigh In On Surrozen
Several institutional investors have recently made changes to their positions in the company. Stempoint Capital LP grew its stake in shares of Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock valued at $6,138,000 after buying an additional 445,713 shares in the last quarter. Braidwell LP acquired a new stake in Surrozen in the second quarter valued at approximately $1,252,000. Millennium Management LLC acquired a new stake in Surrozen in the third quarter valued at approximately $1,414,000. Schonfeld Strategic Advisors LLC bought a new stake in Surrozen in the third quarter worth approximately $889,000. Finally, Armistice Capital LLC acquired a new position in shares of Surrozen during the 2nd quarter worth $536,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.
The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
